Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Stephan Schorn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6811-1220; OpenAlex author ID A5033509794. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 17

  1. Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.109018↗
  2. A retrospective, multicentric, nationwide analysis of the impact of splenectomy on survival of pancreatic cancer patients. Co-author DOI 10.1007/s00423-024-03570-y↗
  3. Lymph node examination and survival in resected pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrad125↗
  4. Arterial Resection for Pancreatic Cancer: Feasibility and Current Standing in a High-Volume Center. Co-author DOI 10.1097/as9.0000000000000302↗
  5. The Effect of Celiac Neurolysis and Splanchnicectomy on Survival in Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. First author DOI 10.1159/000520456↗
  6. [Nutritional therapies for patients with pancreatic cancer]. Co-author DOI 10.1007/s15006-020-4495-4↗
  7. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  8. The quality of pain management in pancreatic cancer: A prospective multi-center study. Co-author DOI 10.1016/j.pan.2020.08.017↗
  9. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  10. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. Co-author DOI 10.21037/tgh.2019.06.01↗
  11. Meta-analysis of the impact of neoadjuvant therapy on patterns of recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/bjs5.46↗
  12. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002345↗
  13. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2017.03.003↗
  14. The influence of neural invasion on survival and tumor recurrence in pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Co-author DOI 10.1016/j.suronc.2017.01.007↗
  15. Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. Co-author DOI 10.1136/gutjnl-2015-309784↗
  16. The neurotrophic factor neurturin contributes toward an aggressive cancer cell phenotype, neuropathic pain and neuronal plasticity in pancreatic cancer. Co-author DOI 10.1093/carcin/bgt312↗
  17. Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis. First author DOI 10.1371/journal.pone.0060529↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guralp Onur Ceyhan · 16 shared papers, 2013–2025 · strength 1.67
  2. İhsan Ekin Demir · 13 shared papers, 2013–2025 · strength 1.40
  3. Helmut Friess · 8 shared papers, 2016–2025 · strength 1.19
  4. Ilaria Pergolini · 4 shared papers, 2022–2024 · strength 0.65
  5. Okan Safak · 4 shared papers, 2022–2024 · strength 0.65
  6. Rüdiger Göß · 4 shared papers, 2017–2024 · strength 0.56
  7. Florian Scheufele · 5 shared papers, 2017–2024 · strength 0.51
  8. Marc Eric Martignoni · 3 shared papers, 2020–2024 · strength 0.49
  9. Alexander Novotny · 3 shared papers, 2023–2024 · strength 0.49
  10. Helmut Frieß · 7 shared papers, 2013–2020 · strength 0.48
  11. Anna Melissa Schlitter · 2 shared papers, 2018–2025 · strength 0.31
  12. Maximilian Kießler · 2 shared papers, 2023–2024 · strength 0.30
  13. Elke Tieftrunk · 5 shared papers, 2014–2018 · strength 0.29
  14. Carmen Mota Reyes · 3 shared papers, 2017–2024 · strength 0.27
  15. Marko Damm · 3 shared papers, 2020 · strength 0.27
  16. John A. G. Moir · 3 shared papers, 2020 · strength 0.27
  17. Maximilian Weniger · 3 shared papers, 2020 · strength 0.27
  18. Jonas Rosendahl · 3 shared papers, 2020 · strength 0.27
  19. Georgios A. Kaissis · 1 shared paper, 2025 · strength 0.24
  20. Matthias M. Gaida · 1 shared paper, 2025 · strength 0.24
  21. Rickmer Braren · 1 shared paper, 2025 · strength 0.24
  22. Jens Werner · 2 shared papers, 2020–2024 · strength 0.21
  23. Jan Goesta D’Haese · 3 shared papers, 2014–2020 · strength 0.20
  24. Patrick Michl · 2 shared papers, 2020 · strength 0.19
  25. Alexander Muckenhuber · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.